Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Cash from Investing Activities (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Cash from Investing Activities for 15 consecutive years, with -$23.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 130.87% year-over-year to -$23.7 million, compared with a TTM value of -$229.9 million through Dec 2025, up 43.64%, and an annual FY2025 reading of -$129.3 million, up 69.22% over the prior year.
  • Cash from Investing Activities was -$23.7 million for Q4 2025 at Arrowhead Pharmaceuticals, down from $72.6 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $141.4 million in Q2 2025 and bottomed at -$420.2 million in Q1 2025.
  • Average Cash from Investing Activities over 5 years is -$42.3 million, with a median of -$21.6 million recorded in 2021.
  • The sharpest move saw Cash from Investing Activities crashed 830.68% in 2024, then skyrocketed 1934.68% in 2025.
  • Year by year, Cash from Investing Activities stood at -$33.4 million in 2021, then tumbled by 141.71% to -$80.7 million in 2022, then soared by 180.35% to $64.8 million in 2023, then rose by 18.62% to $76.9 million in 2024, then crashed by 130.87% to -$23.7 million in 2025.
  • Business Quant data shows Cash from Investing Activities for ARWR at -$23.7 million in Q4 2025, $72.6 million in Q3 2025, and $141.4 million in Q2 2025.